Shares of Merck & Co. (NYSE:MRK) fell 3.7% on Tuesday after the company and partner Eisai disclosed that their Phase 3 LITESPARK-012 study failed to achieve its primary endpoints in advanced renal cell carcinoma.
The international study enrolled 1,688 patients with advanced clear cell renal cell carcinoma and evaluated two experimental combination regimens against the control arm of Keytruda plus Lenvima. At a pre-specified interim analysis, neither experimental approach showed improved progression-free survival or overall survival compared with the control.
One investigational arm combined Keytruda, Lenvima, and Welireg, while the other tested MK-1308A in combination with Lenvima. The companies indicated that safety profiles observed in the trial were in line with previously recorded data for the individual agents.
In a prepared statement, Dr. M. Catherine Pietanza, Vice President of Global Clinical Development at MSD Research Laboratories, said that although the regimens did not deliver the expected outcomes, the findings add to the clinical understanding of advanced renal cell carcinoma and will inform future development strategies.
Separately, Bloomberg Intelligence analyst John Morphy assessed the commercial implications for Welireg. He estimated that the setback in first-line kidney cancer could reduce his 2030 sales forecast for Welireg by roughly $300 million, a decrease of about 13% for that product. Morphy added that the broader impact on Merck is modest, representing less than 1% of company-wide sales, and suggested that the LITESPARK-012 results likely end Welireg's opportunity in first-line renal cell carcinoma given the absence of other ongoing studies.
The announcement does not alter other active trials within the LITESPARK development program. The Food and Drug Administration has accepted two supplemental New Drug Applications based on the Phase 3 LITESPARK-011 trial and assigned a target action date of October 4, 2026.
Renal cell carcinoma is the most common form of kidney cancer; records show about 435,000 new cases worldwide in 2022.
Key takeaways
- Merck shares dropped 3.7% after the Phase 3 LITESPARK-012 trial failed to meet primary endpoints for advanced clear cell renal cell carcinoma.
- Neither the Keytruda-Lenvima-Welireg combination nor MK-1308A plus Lenvima improved progression-free survival or overall survival versus Keytruda plus Lenvima at interim analysis.
- Safety findings were consistent with prior data; the result affects Welireg's first-line prospects but has limited impact on Merck's total sales according to an analyst.
Risks and uncertainties
- The LITESPARK-012 interim results raise uncertainty about Welireg's potential in first-line renal cell carcinoma, affecting product-level revenue forecasts in oncology.
- Market reaction to the trial outcome may increase short-term volatility in Merck's stock price and investor sentiment toward oncology investments.
- Future regulatory actions remain subject to the outcomes of other LITESPARK studies; the FDA has a pending review with an October 4, 2026 action date for submissions tied to LITESPARK-011.
The companies and their clinical teams will likely review the full dataset to guide next steps in development, while stakeholders monitor ongoing LITESPARK trials and regulatory timelines for additional clarity.